DK1163250T3 - Forbedret syntese af [2.2.1]bicyclonukleosider - Google Patents

Forbedret syntese af [2.2.1]bicyclonukleosider

Info

Publication number
DK1163250T3
DK1163250T3 DK00912410T DK00912410T DK1163250T3 DK 1163250 T3 DK1163250 T3 DK 1163250T3 DK 00912410 T DK00912410 T DK 00912410T DK 00912410 T DK00912410 T DK 00912410T DK 1163250 T3 DK1163250 T3 DK 1163250T3
Authority
DK
Denmark
Prior art keywords
general formula
synthesis
instance
formula iii
bicyclo
Prior art date
Application number
DK00912410T
Other languages
English (en)
Inventor
Alexei Kochkine
Jef Fensholdt
Henrik M Pfundheller
Original Assignee
Exiqon As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exiqon As filed Critical Exiqon As
Application granted granted Critical
Publication of DK1163250T3 publication Critical patent/DK1163250T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
DK00912410T 1999-03-24 2000-03-24 Forbedret syntese af [2.2.1]bicyclonukleosider DK1163250T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900407 1999-03-24
DKPA200000099 2000-01-21
EP00912410A EP1163250B1 (en) 1999-03-24 2000-03-24 Improved synthesis of ¬2.2.1|bicyclo nucleosides

Publications (1)

Publication Number Publication Date
DK1163250T3 true DK1163250T3 (da) 2006-11-13

Family

ID=26063935

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912410T DK1163250T3 (da) 1999-03-24 2000-03-24 Forbedret syntese af [2.2.1]bicyclonukleosider

Country Status (10)

Country Link
US (1) US6639059B1 (da)
EP (1) EP1163250B1 (da)
JP (1) JP4768132B2 (da)
AT (1) ATE332909T1 (da)
AU (1) AU3418800A (da)
DE (1) DE60029314T2 (da)
DK (1) DK1163250T3 (da)
ES (1) ES2269113T3 (da)
IL (1) IL145496A0 (da)
WO (1) WO2000056746A2 (da)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE332909T1 (de) * 1999-03-24 2006-08-15 Exiqon As Verbesserte synthese für 2.2.1.öbicyclo- nukleoside
US6734291B2 (en) * 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
EP1263773A4 (en) 2000-03-14 2005-08-31 Active Motif OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF IMPLEMENTATION
EP1334109B1 (en) 2000-10-04 2006-05-10 Santaris Pharma A/S Improved synthesis of purine locked nucleic acid analogues
EP1446412B1 (en) 2001-09-04 2012-03-07 Exiqon A/S Novel lna compositions and uses thereof
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
ATE508188T1 (de) 2002-02-01 2011-05-15 Life Technologies Corp Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
DK2264172T3 (da) 2002-04-05 2017-11-27 Roche Innovation Ct Copenhagen As Oligomerforbindelser til modulering af HIF-1á-ekspression
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
AU2003243541A1 (en) * 2002-06-12 2003-12-31 Ambion, Inc. Methods and compositions relating to labeled rna molecules that reduce gene expression
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
DE602004022020D1 (de) 2003-02-10 2009-08-27 Santaris Pharma As Oligomere verbindungen zur modulation der expression von survivin
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
DK2141234T3 (da) 2003-03-21 2016-06-20 Roche Innovation Ct Copenhagen As Korte interfererende RNA (siRNA) analoger
CN1833034B (zh) 2003-06-20 2014-04-16 埃克斯魁恩公司 用于分析核酸混合物的探针、文库和试剂盒及其构建方法
KR20070006709A (ko) * 2003-12-23 2007-01-11 산타리스 팔마 에이/에스 Ｂｃｌ-2의 조절을 위한 올리고머 화합물
US8192937B2 (en) 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
WO2006085964A2 (en) 2004-06-30 2006-08-17 Applera Corporation Log-linear amplification
US20090118132A1 (en) * 2004-11-04 2009-05-07 Roche Molecular Systems, Inc. Classification of Acute Myeloid Leukemia
BRPI0517613A (pt) 2004-11-09 2008-10-14 Santaris Pharma As oligonucleotìdeos lna e tratamento de cáncer
EP1833840B9 (en) 2004-11-09 2010-11-10 Santaris Pharma A/S Potent lna oligonucleotides for the inhibition of hif-1a
US7842794B2 (en) 2004-12-17 2010-11-30 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
EP1959012A3 (en) 2004-12-29 2009-12-30 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
US7838502B2 (en) 2005-05-06 2010-11-23 University Of Massachusetts Medical School Compositions and methods to modulate H. influenzae pathogenesis
US7919242B2 (en) 2005-06-30 2011-04-05 Roche Molecular Systems, Inc. Light emission modifiers and their uses in nucleic acid detection, amplification and analysis
EP1971371B1 (en) 2005-12-01 2015-08-05 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
CN101437933B (zh) 2005-12-28 2013-11-06 斯克里普斯研究所 作为药物靶标的天然反义和非编码的rna转录物
US7296313B2 (en) * 2006-01-13 2007-11-20 Matthaus Hense Inflatable knee pillow having thin profile and foldability when deflated
US8329888B2 (en) 2006-03-23 2012-12-11 Santaris Pharma A/S Small internally segmented interfering RNA
DK2666859T3 (da) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As FARMACEUTISK SAMMENSÆTNING, DER OMFATTER ANTI-miRNA-ANTISENSE-OLIGONUKLEOTIDER
CN102851291B (zh) 2006-04-03 2016-03-09 斯特拉有限责任公司 包含抗微小rna反义寡核苷酸的药物组合物
US20080050752A1 (en) 2006-06-30 2008-02-28 Applera Corporation Methods of analyzing binding interactions
WO2008046911A2 (en) 2006-10-20 2008-04-24 Exiqon A/S Novel human micrornas associated with cancer
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
EP2118118B1 (en) 2007-01-19 2017-09-27 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
ES2798758T3 (es) 2007-06-06 2020-12-14 Sarepta Therapeutics Inc Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
US8299237B2 (en) 2007-08-30 2012-10-30 Hadasit Medical Research Services & Development Ltd. Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders
EP2548962B1 (en) 2007-09-19 2016-01-13 Applied Biosystems, LLC Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
EP2212437A4 (en) 2007-11-07 2011-09-28 Univ British Columbia MICROFLUIDIC DEVICE AND METHOD OF USING THE DEVICE
ES2916498T3 (es) 2007-12-06 2022-07-01 Genalyte Inc Método para identificar una secuencia de nucleótidos en una especie desconocida de ácido nucleico; y dispositivo para llevar a cabo el método
EP3699291A1 (en) 2008-01-17 2020-08-26 Sequenom, Inc. Single molecule nucleic acid sequence analysis processes and compositions
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US10150990B2 (en) 2008-04-21 2018-12-11 Roche Molecular Systems, Inc. Ribonucleotide tag nucleic acid detection
CA2635187A1 (en) 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
CA2726850C (en) 2008-06-13 2015-06-02 Codexis, Inc. Method of synthesizing polynucleotide variants
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
KR101770435B1 (ko) 2008-10-03 2017-09-05 큐알엔에이, 인크. 자연 안티센스 전사체가 아포리포단백질-ａ1로 억제에 의해 아포리포단백-ａ1 관련된 질환의 치료
US9846126B2 (en) 2008-10-27 2017-12-19 Genalyte, Inc. Biosensors based on optical probing and sensing
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
ES2629630T3 (es) 2008-12-04 2017-08-11 Curna, Inc. Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
US8206929B2 (en) 2009-01-07 2012-06-26 Roche Molecular Systems, Inc. Nucleic acid amplification with allele-specific suppression of sequence variants
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
ES2762610T3 (es) 2009-02-12 2020-05-25 Curna Inc Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
MX2011009751A (es) 2009-03-16 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101742334B1 (ko) 2009-05-08 2017-06-01 큐알엔에이, 인크. Ｄｍｄ 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
CN102575251B (zh) 2009-05-18 2018-12-04 库尔纳公司 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
CN103221541B (zh) 2009-05-28 2017-03-01 库尔纳公司 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US9234199B2 (en) 2009-08-05 2016-01-12 Curna, Inc. Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
EP2464731B1 (en) 2009-08-11 2016-10-05 CuRNA, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8409802B2 (en) 2009-08-14 2013-04-02 Roche Molecular Systems, Inc. Format of probes to detect nucleic acid differences
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
EP2480669B1 (en) 2009-09-25 2017-11-08 CuRNA, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
ES2661813T3 (es) 2009-12-16 2018-04-04 Curna, Inc. Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
US9404160B2 (en) 2009-12-22 2016-08-02 Becton, Dickinson And Company Methods for the detection of microorganisms
WO2011087760A2 (en) 2009-12-22 2011-07-21 Sequenom, Inc. Processes and kits for identifying aneuploidy
CA2782373C (en) 2009-12-23 2019-03-26 Opko Curna, Llc Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
WO2011090740A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
ES2585829T3 (es) 2009-12-29 2016-10-10 Curna, Inc. Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
US20120289583A1 (en) 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
KR101878501B1 (ko) 2010-01-04 2018-08-07 큐알엔에이, 인크. 인터페론 조절 인자 8 (ｉｒｆ8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (ｉｒｆ8) 관련된 질환의 치료
EP2521785B1 (en) 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
DK2524039T3 (da) 2010-01-11 2018-03-12 Curna Inc Behandling af kønshormonbindende globulin- (shbg) relaterede sygdomme ved hæmning af naturligt antisense-transskript mod shbg
CN102782135A (zh) 2010-01-25 2012-11-14 库尔纳公司 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
ES2657969T3 (es) 2010-04-02 2018-03-07 Curna, Inc. Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3
RU2610661C2 (ru) 2010-04-09 2017-02-14 Курна, Инк. Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
SG184938A1 (en) 2010-04-30 2012-11-29 Exiqon As In situ hybridization method and buffer
CN107988228B (zh) 2010-05-03 2022-01-25 库尔纳公司 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799596C (en) 2010-05-26 2020-09-22 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
KR102008708B1 (ko) 2010-06-23 2019-08-08 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP3372684B1 (en) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Single-stranded rnai agents containing an internal, non-nucleic acid spacer
EP2625274B1 (en) 2010-10-06 2017-07-19 CuRNA, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
EP3733866B1 (en) 2010-11-05 2023-11-15 Genalyte, Inc. Optical analyte detection systems and methods of use
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
CN103459599B (zh) 2010-11-23 2017-06-16 库尔纳公司 通过抑制nanog的天然反义转录物而治疗nanog相关疾病
EP3733870A3 (en) 2011-01-14 2021-01-27 Life Technologies Corporation Methods for identification and quantification of mirnas
JP6188686B2 (ja) 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療
CA2847811C (en) 2011-09-06 2019-10-22 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules
EP4155401A1 (en) 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP2825885B1 (en) 2012-03-12 2021-05-12 The Board of Trustees of the University of Illinois Optical analyte detection systems with magnetic enhancement
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9359616B2 (en) 2012-05-21 2016-06-07 The Scripps Research Institute Ribosomal polynucleotides and related expression systems
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
CA2878979C (en) 2012-07-13 2021-09-14 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
JP2016509572A (ja) 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Ｂｃｌ２発現の調節による癌の処置のためにバイオマーカーを使用する方法
WO2014108759A1 (en) 2013-01-14 2014-07-17 Pierfrancesco Tassone INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
US10086093B2 (en) 2013-02-28 2018-10-02 The General Hospital Corporation miRNA profiling compositions and methods of use
WO2014168711A1 (en) 2013-03-13 2014-10-16 Sequenom, Inc. Primers for dna methylation analysis
WO2014143637A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
US9828629B2 (en) 2013-03-15 2017-11-28 Roche Molecular Systems, Inc. Nucleic acid target identification by structure based probe cleavage
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
KR20160068855A (ko) 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 억제제 및 사용 방법
MX367192B (es) 2013-10-30 2019-08-08 Green Life Biotech Llc Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos.
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
US9637791B2 (en) 2013-12-20 2017-05-02 Roche Molecular Systems, Inc. Multiplexed nucleic acid target identification by strucutre based probe cleavage
WO2015118407A2 (en) 2014-01-29 2015-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
EP3117011B1 (en) 2014-03-13 2020-05-06 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2016041058A1 (en) 2014-09-18 2016-03-24 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
US9976143B2 (en) 2014-10-03 2018-05-22 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
TWI698444B (zh) * 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
EP3359685A1 (en) 2015-10-09 2018-08-15 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US10905710B2 (en) 2016-05-24 2021-02-02 Emory University Particles with RNA cleaving nucleobase polymers and uses for managing inflammatory disorders
US20220354888A1 (en) 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
US11147249B2 (en) 2016-12-08 2021-10-19 Alector Llc Siglec transgenic mice and methods of use thereof
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CN117700548A (zh) 2017-08-03 2024-03-15 艾利妥 抗cd33抗体及其使用方法
CN111278991B (zh) 2017-08-25 2022-04-01 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
EP3697904A1 (en) 2017-10-17 2020-08-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
KR102627534B1 (ko) 2018-06-21 2024-01-19 에프. 호프만-라 로슈 아게 전부-lna 올리고뉴클레오티드 혼성화
WO2020023920A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CN110818748A (zh) * 2018-08-07 2020-02-21 广州市锐博生物科技有限公司 核苷化合物与其中间体的合成方法
US20210308215A1 (en) 2018-09-21 2021-10-07 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mrna coding for secreted proteins
WO2020099533A1 (en) 2018-11-16 2020-05-22 F. Hoffmann-La Roche Ag Streptavidin-coated solid phases with a member of a binding pair
WO2020245377A1 (en) 2019-06-07 2020-12-10 F. Hoffmann-La Roche Ag Hybridizing all-lna oligonucleotides
WO2021005223A1 (en) 2019-07-10 2021-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of epilepsy
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
EP4061943A1 (en) 2019-11-19 2022-09-28 Institut National de la Santé et de la Recherche Médicale (INSERM) Antisense oligonucleotides and their use for the treatment of cancer
CA3173647A1 (en) 2020-05-11 2021-11-18 Isabel AZNAREZ Opa1 antisense oligomers for treatment of conditions and diseases
US20210381039A1 (en) 2020-05-29 2021-12-09 Front Range Biosciences, Inc. Methods and compositions for pathogen detection in plants
WO2022006019A1 (en) 2020-06-29 2022-01-06 Front Range Biosciences, Inc. Characterization of cannabis cultivars based on terpene synthase gene profiles
JP2023540429A (ja) 2020-07-10 2023-09-25 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） てんかんを治療するための方法及び組成物
KR20230144588A (ko) 2021-02-12 2023-10-16 머랜드 파마슈티칼스, 인크. 저산소증 및 허혈-관련 장애의 치료를 위한 작용제, 조성물 및 방법
CN117479947A (zh) 2021-03-26 2024-01-30 神经微核糖核酸治疗有限公司 微RNA-27b抑制剂
JP2024510663A (ja) 2021-03-26 2024-03-08 ニューミルナ セラピューティクス エーピーエス マイクロｒｎａ－１３４阻害剤
CN117642505A (zh) 2021-06-04 2024-03-01 神经微核糖核酸治疗有限公司 靶向腺苷激酶的反义寡核苷酸
AU2022329834A1 (en) 2021-08-17 2024-03-07 Korea Advanced Institute Of Science And Technology Antisense oligonucleotide targeting cav3.1 gene and uses thereof
WO2023021184A1 (en) 2021-08-19 2023-02-23 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
US20230159930A1 (en) 2021-11-19 2023-05-25 Sanegene Bio Usa Inc. Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
WO2023104812A1 (en) 2021-12-09 2023-06-15 F. Hoffmann-La Roche Ag Mass based detection of pcr amplicons
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
US20240002857A1 (en) 2022-05-09 2024-01-04 Sanegene Bio Usa Inc. Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
WO2024031101A1 (en) 2022-08-05 2024-02-08 Sanegene Bio Usa Inc. Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
WO2024081954A2 (en) 2022-10-14 2024-04-18 Sanegene Bio Usa Inc. Small interfering rna targeting c3 and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
JPH0680688A (ja) * 1992-09-03 1994-03-22 Asahi Breweries Ltd ４’−メチルヌクレオシド誘導体
ES2192672T3 (es) * 1996-11-18 2003-10-16 Takeshi Imanishi Nuevos analogos de nucleotidos.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
IL135000A0 (en) * 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
EP1161439B1 (en) * 1999-03-18 2010-04-21 Exiqon A/S Xylo-lna analogues
ATE332909T1 (de) * 1999-03-24 2006-08-15 Exiqon As Verbesserte synthese für 2.2.1.öbicyclo- nukleoside
KR100782896B1 (ko) * 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
WO2000078775A1 (fr) * 1999-06-22 2000-12-28 Sankyo Company, Limited Nouveaux nucleosides pontes en 3'-4' et analogues d'oligonucleotides

Also Published As

Publication number Publication date
AU3418800A (en) 2000-10-09
ES2269113T3 (es) 2007-04-01
EP1163250B1 (en) 2006-07-12
ATE332909T1 (de) 2006-08-15
JP2002540116A (ja) 2002-11-26
JP4768132B2 (ja) 2011-09-07
US6639059B1 (en) 2003-10-28
EP1163250A2 (en) 2001-12-19
DE60029314D1 (de) 2006-08-24
WO2000056746A3 (en) 2001-10-18
DE60029314T2 (de) 2007-07-12
WO2000056746A2 (en) 2000-09-28
IL145496A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
DK1163250T3 (da) Forbedret syntese af [2.2.1]bicyclonukleosider
Liu et al. Size-expanded analogues of dG and dC: synthesis and pairing properties in DNA
Beauchamp et al. Effect of acyclic pyrimidines related to 9-[(1, 3-dihydroxy-2-propoxy) methyl] guanine on herpes viruses
US5814639A (en) Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
AU614105B2 (en) Purinyl and pyrimidinyl cyclobutanes
WO2000066604A3 (en) L-ribo-lna analogues
Jenny et al. Carbocyclic analogs of nucleosides via modified Mitsunobu reactions
ATE336492T1 (de) Methonocarbacycloalkylanaloga von nucleosiden
Hari et al. Synthesis and properties of 2′-O, 4′-C-methyleneoxymethylene bridged nucleic acid
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO1995035102A1 (en) Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
NZ507913A (en) Novel nucleosides having bicyclic sugar moiety
Khalifa et al. HIV-1 and HSV-1 virus activities of some new polycyclic nucleoside pyrene candidates
Goudgaon et al. Phenylselenenyl-and phenylthio-substituted pyrimidines as inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase
MX2022016492A (es) Nucleosidos y nucleotidos con grupo de bloqueo de acetal 3'.
KR890008161A (ko) 2',3'-디데옥시-2'-플루오로뉴클레오사이드류
Danel et al. Anti-HIV active naphthyl analogues of HEPT and DABO
Nguyen-Ba et al. Synthesis and antiviral activities of N-9-oxypurine 1, 3-Dioxolane and 1, 3-oxathiolane nucleosides
HUP0301038A2 (hu) Eljárás 4,6-dimetoxi-2-(metil-szulfonil)-1,3-pirimidin elõállítására
Hammarström et al. Utility of 4, 6-dichloro-2-(methylthio)-5-nitropyrimidine. Part 2: Solution phase synthesis of tetrasubstituted purines
Gupta et al. Facile, chemoenzymatic synthesis of the potent antiviral compound, 2-acetonylinosine
JP2001517659A5 (da)
Egron et al. 1, 3-Dihydrobenzo [c] furan nucleoside analogues: additional studies of the thymine derivative
Manfredini et al. Design, synthesis and enzymatic activity of highly selective human mitochondrial thymidine kinase inhibitors
Kundu et al. Palladium-catalysed synthesis of 6-(2-acylvinyl) uracils, a group of novel 6-substituted uracils of biological significance